The trial lead sat in a high-stakes protocol review meeting, subtly tilting their laptop screen away from the digital...

In prior adult Phase 1/2 data, VAX-31 produced robust opsonophagocytic activity across all 31 serotypes, met superiority criteria on...

Early Phase 1 signals from Senti Biosciences’ off-the-shelf CAR-NK program in relapsed/refractory AML include MRD-negative, durable complete remissions with...

Upstream Bio’s Phase 2 VALIANT study in severe asthma cut annualized asthma exacerbation rate by 56% with verekitug 100...

Clinical remission was achieved in 63.2% (12/19) of patients treated with MB310 versus 30.0% (3/10) on placebo in an...

PathAI has expanded its AISight Clinical Trials platform for inflammatory bowel disease with the launch of IBDExplore, joining its...

Septerna will present first-in-human, proof‑of‑mechanism data for SEP‑631, an oral MRGPRX2 negative allosteric modulator, at the AAAAI Annual Meeting...

Aardvark Therapeutics secured U.S. IRB approval to amend its Phase 3 HERO protocol, lowering the minimum enrollment age from...

In prior testing, teverelix achieved rapid testosterone suppression with a 97.5% probability of castration shortly after dosing in a...

Clearmind reported no serious adverse events and continued good tolerability in six additional patients completing treatment in the second...